HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

被引:146
作者
Pugach, Pavel [1 ]
Marozsan, Andre J. [1 ]
Ketas, Thomas J. [1 ]
Landes, Elissa L. [1 ]
Moore, John P. [1 ]
Kuhmann, Shawn E. [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA
关键词
HIV-1; CCR5; entry inhibition; resistance; escape mutants;
D O I
10.1016/j.virol.2006.11.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus type 1 (HIV-1) infection can be inhibited by small molecules that target the CCR5 coreceptor. Here, we describe some properties of clonal viruses resistant to one such inhibitor, SCH-D, using both chimeric, infectious molecular clones and Envpseudotypes. Studies using combinations of CCR5 ligands, including small molecule inhibitors, monoclonal antibodies (MAbs) and chemokine derivatives such as PSC-RANTES, show that the fully SCH-D-resistant viruses enter target cells by using the SCH-D-bound form of CCR5. However, the way resistance to SCH-D and other small molecule CCR5 inhibitors is manifested depends on the target cell and the nature of the assay (single- vs. multi-cycle). In multi-cycle assays using primary lymphocytes, SCH-D does not inhibit resistant molecular clones, and it can even enhance their infectivity modestly. In contrast, the same viruses (as Env-pseudotypes) are significantly inhibited by SCH-D in single-cycle entry assays using U87-CD4/CCR5 cells, resistance being manifested by incomplete inhibition at high SCH-D concentrations. When a single-cycle, Env-pseudotype entry assay was performed using either U87-CD4/CCR5 cells or PBMC under comparable conditions, entry was inhibited by up to 88% in the former cells but by only 28% in the PBMC. Hence, there are both cell- and assay-dependent influences on how resistance is manifested. We also take this opportunity to correct our previous report that SCH-D-resistant isolates are also substantially cross-resistant to PSC-RANTES [Marozsan, A.J., Kuhmann, S.E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B.M., Strizki, J., Moore, J.P., 2005. Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338 (1), 182-199]. A substantial element of this resistance was attributable to the unappreciated carry-over of SCH-D from the selection cultures into analytical assays. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:212 / 228
页数:17
相关论文
共 41 条
  • [1] Anonymous, 2005, Antiviral Chemistry & Chemotherapy, V16, P339
  • [2] The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors
    Billick, E
    Seibert, C
    Pugach, P
    Ketas, T
    Trkola, A
    Endres, MJ
    Murgolo, NJ
    Coates, E
    Reyes, GR
    Baroudy, BM
    Sakmar, TP
    Moore, JP
    Kuhmann, SE
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (08) : 4134 - 4144
  • [3] BJOMDAL A, 1997, J VIROL, V71, P7478
  • [4] Assessing chemokine co-receptor usage in HIV
    Coakley, E
    Petropoulos, CJ
    Whitcomb, JM
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2005, 18 (01) : 9 - 15
  • [5] The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor
    Cormier, EG
    Dragic, T
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (17) : 8953 - 8957
  • [6] Mapping the determinants of the CCRS amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes
    Cormier, EG
    Tran, DNH
    Yukhayeva, L
    Olson, WC
    Dragic, T
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (12) : 5541 - 5549
  • [7] A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
    Dragic, T
    Trkola, A
    Thompson, DAD
    Cormier, EG
    Kajumo, FA
    Maxwell, E
    Lin, SW
    Ying, WW
    Smith, SO
    Sakmar, TP
    Moore, JP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5639 - 5644
  • [8] HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5
    Dragic, T
    Litwin, V
    Allaway, GP
    Martin, SR
    Huang, YX
    Nagashima, KA
    Cayanan, C
    Maddon, PJ
    Koup, RA
    Moore, JP
    Paxton, WA
    [J]. NATURE, 1996, 381 (6584) : 667 - 673
  • [9] Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    Fätkenheuer, G
    Pozniak, AL
    Johnson, MA
    Plettenberg, A
    Staszewski, S
    Hoepelman, AIM
    Saag, MS
    Goebel, FD
    Rockstroh, JK
    Dezube, BJ
    Jenkins, TM
    Medhurst, C
    Sullivan, JF
    Ridgway, C
    Abel, S
    James, IT
    Youle, M
    van der Ryst, E
    [J]. NATURE MEDICINE, 2005, 11 (11) : 1170 - 1172
  • [10] Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate
    Gorry, PR
    Taylor, J
    Holm, GH
    Mehle, A
    Morgan, T
    Cayabyab, M
    Farzan, M
    Wang, H
    Bell, JE
    Kunstman, K
    Moore, JP
    Wolinsky, SM
    Gabuzda, D
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (12) : 6277 - 6292